



Innovative Medicines Initiative

Programme

**Public Private Partnerships Boost Alzheimer's Disease Drug Discovery.**  
IMI Official Satellite Symposium of the AD/PD 2011 Conference,  
9th March 2011, Barcelona Spain  
Hall C

8:00-8:30	Registration, Coffee and Welcome : <i>Elisabetta Vaudano (Innovative Medicines Initiative, Belgium)</i>
8:30-09:20	<b>Setting the Scene:</b> <i>Rivka Ravid (Brainbank Consultants, The Netherlands):</i> From Specimen to Bio marker? Harmonisation of Bio bank SOP's in the Discovery of Novel Candidate Bio markers for Alzheimer's Disease (AD). <i>Mony de Leon (Center for Brain Health NYU, USA):</i> Biomarkers useful for detecting presymptomatic AD are also useful in revealing mechanisms of disease.
9:20-10:25	<b>New European Research Models to Boost Progress in AD Research</b> <i>Elisabetta Vaudano (Innovative Medicines Initiative, Belgium)</i> Introduction to the Innovative Medicines Initiative. <i>Ejner K. Moltzen (Lundbeck, Denmark):</i> Why IMI: the industrial perspective. <i>Elisabetta Vaudano (IMI, Belgium):</i> European Union Support (FP7) for Joint Programming Initiatives: the Joint Programming on Neurodegenerative Diseases, JPND
10:25 - 10:35	Break
10:35-11:45	<b>PharmaCog: Tackling the bottlenecks in AD Drug discovery</b> <i>Mike O'Neil (Eli Lilly, United Kingdom):</i> PharmaCog: AD Drug discovery from bench to bedside. <i>Alexandra Auffret (Centre d'Investigation Clinique Hôpital de la Timone, France):</i> Tools to improve decision making in drug development. <i>Mike O'Neil (Eli Lilly, United Kingdom):</i> Towards better clinical study designs. <i>Jean Georges (Alzheimer Europe, Luxembourg):</i> Bringing the patient's perspective to drug discovery challenges.
11:45-12:10	<b>Getting the broad picture: from Europe, to US and beyond</b> <i>Marc Cantillon (CAMD, The Critical Path Institute, USA):</i> Global regulatory qualification of biomarkers in AD
12:10-12:25	General Discussion, Round Table

